TY - CHAP M1 - Book, Section TI - Warfarin A1 - CHU, VALERY L. A1 - MALTZ, HELENE C. A2 - Cohen, Henry Y1 - 2015 N1 - T2 - Casebook in Clinical Pharmacokinetics and Drug Dosing AB - Following the isolation of hemorrhagic agents from spoiled sweet clover hay in the 1930s and development of 3-phenyacetyl ethyl, 4-hydroxycoumarin as a rat poison in 1948, warfarin has been the primary oral anticoagulant used in North America since its approval for medical use in 1954.1 Even following the availability of new oral anticoagulant classes, it is widely used for its various indications including prophylaxis and treatment of venous thrombosis and pulmonary embolism, prophylaxis and treatment of thromboembolic complications of atrial fibrillation and heart valve replacement, and postmyocardial infarction (MI) reduction in the risk of death, recurrent MI, and thromboembolic events such as stroke or systemic embolization.2 SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/03/29 UR - accesspharmacy.mhmedical.com/content.aspx?aid=1112259866 ER -